<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;C09A&quot;,&quot;href&quot;:&quot;atc/C09A.md&quot;},{&quot;label&quot;:&quot;quinapril&quot;}]"></div>

# quinapril

- **generic name:** quinapril
- **ATC codes:** `C09AA06`, `C09BA06`
- **DrugBank:** [DB00881](https://go.drugbank.com/drugs/DB00881) · **PubChem:** [CID 54892](https://pubchem.ncbi.nlm.nih.gov/compound/54892)
- **molar mass:** 438.5161 g/mol (C25H30N2O5) — DrugBank
- **groups:** approved, investigational

## About

Quinapril is an ACE inhibitor used to treat high blood pressure and congestive heart failure. It is an approved medicine, available alone or combined with a diuretic, and is used fairly widely for these cardiovascular conditions.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q596022](https://www.wikidata.org/wiki/Q596022) and the WHO ATC classification; not checked by a person.</small>

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-30 23:42 | 2:14 | 0/0/0 | 1/1/0 | 0/0/2 | 63,171/10,152 | ollama / glm-5.3-flash | 7 | 8/6 | 0/7 | 0 |

## popPK records

_not available_

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> | [Breslin_1996_A_I_pressor_response](drugs/drug_quinapril/pd_Breslin_1996_A_I_pressor_response.md) | angiotensin I pressor response ← quinaprilat · inhibition effect | — | Breslin E et al., A pharmacodynamic and pharmacokinetic c…, Journal of clinical pharmac… (1996) | [10.1002/j.1552-4604.1996.tb05028.x](https://doi.org/10.1002/j.1552-4604.1996.tb05028.x) |
| <span class="pk-badge pk-badge--green">extracted</span> | [Breslin_1996_plasma_ACE_activity](drugs/drug_quinapril/pd_Breslin_1996_plasma_ACE_activity.md) | plasma ACE activity ← quinaprilat · inhibition effect | — | Breslin E et al., A pharmacodynamic and pharmacokinetic c…, Journal of clinical pharmac… (1996) | [10.1002/j.1552-4604.1996.tb05028.x](https://doi.org/10.1002/j.1552-4604.1996.tb05028.x) |
| <span class="pk-badge pk-badge--red">rejected</span> | [Begg_1990_ACE](drugs/drug_quinapril/pd_Begg_1990_ACE.md) | ACE activity ← quinaprilat · direct Emax (saturable) effect | — | Begg EJ et al., The pharmacokinetics and pharmacodynami…, British journal of clinical… (1990) | [10.1111/j.1365-2125.1990.tb03767.x](https://doi.org/10.1111/j.1365-2125.1990.tb03767.x) |
| <span class="pk-badge pk-badge--red">rejected</span> | [Begg_1990_ANP](drugs/drug_quinapril/pd_Begg_1990_ANP.md) | atrial natriuretic peptide ← quinaprilat · direct Emax (saturable) effect | — | Begg EJ et al., The pharmacokinetics and pharmacodynami…, British journal of clinical… (1990) | [10.1111/j.1365-2125.1990.tb03767.x](https://doi.org/10.1111/j.1365-2125.1990.tb03767.x) |
| <span class="pk-badge pk-badge--red">rejected</span> | [Begg_1990_BP](drugs/drug_quinapril/pd_Begg_1990_BP.md) | blood pressure ← quinaprilat · direct Emax (saturable) effect | — | Begg EJ et al., The pharmacokinetics and pharmacodynami…, British journal of clinical… (1990) | [10.1111/j.1365-2125.1990.tb03767.x](https://doi.org/10.1111/j.1365-2125.1990.tb03767.x) |
| <span class="pk-badge pk-badge--red">rejected</span> | [Begg_1990_GFR](drugs/drug_quinapril/pd_Begg_1990_GFR.md) | glomerular filtration rate (Tc99mDTPA clearance) ← quinaprilat · direct Emax (saturable) effect | — | Begg EJ et al., The pharmacokinetics and pharmacodynami…, British journal of clinical… (1990) | [10.1111/j.1365-2125.1990.tb03767.x](https://doi.org/10.1111/j.1365-2125.1990.tb03767.x) |
| <span class="pk-badge pk-badge--red">rejected</span> | [Begg_1990_PRA](drugs/drug_quinapril/pd_Begg_1990_PRA.md) | plasma renin activity ← quinaprilat · direct Emax (saturable) effect | — | Begg EJ et al., The pharmacokinetics and pharmacodynami…, British journal of clinical… (1990) | [10.1111/j.1365-2125.1990.tb03767.x](https://doi.org/10.1111/j.1365-2125.1990.tb03767.x) |
| <span class="pk-badge pk-badge--red">rejected</span> | [Begg_1990_unknown](drugs/drug_quinapril/pd_Begg_1990_unknown.md) | aldosterone ← quinaprilat · direct Emax (saturable) effect | — | Begg EJ et al., The pharmacokinetics and pharmacodynami…, British journal of clinical… (1990) | [10.1111/j.1365-2125.1990.tb03767.x](https://doi.org/10.1111/j.1365-2125.1990.tb03767.x) |

## Pharmacogenomics (PGx)

| status | gene | affects | mechanism | detail | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> | **ACE** | `Q320` · Emax | target | [Pérez-Castrillón_2003](drugs/drug_quinapril/pgx_P_rez_Castrill_n_2003_ACE_Q320.md) | Pérez-Castrillón JL et al., Effect of quinapril, quinapril-hydrochl…, American journal of hyperte… (2003) | [10.1016/s0895-7061(03)00845-8](https://doi.org/10.1016/s0895-7061(03)00845-8) |
| <span class="pk-badge pk-badge--neutral" title="the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.">qualitative</span> | **CES1** | `Q370` · CLfm | formation | [Tarkiainen_2015](drugs/drug_quinapril/pgx_Tarkiainen_2015_CES1_Q370.md) | Tarkiainen EK et al., Effect of carboxylesterase 1 c.428G &gt; A…, British journal of clinical… (2015) | [10.1111/bcp.12667](https://doi.org/10.1111/bcp.12667) |

<details class="pk-legend"><summary>What the PGx badges mean — evidence, and whether a model runs</summary><table><tbody><tr><td><span class="pk-badge pk-badge--green">quantitative</span></td><td>the paper gives the effect of each phenotype (or genotype) on a named model parameter — a θ per category.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">qualitative</span></td><td>the paper links the gene to the drug but states no effect size on a model parameter, so it changes no model.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">guideline estimate</span></td><td>the effect comes from a CPIC / DPWG dosing guideline, not from this paper's numbers.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">safety allele</span></td><td>a risk allele for an adverse reaction (an HLA type, G6PD deficiency …): it changes no PK/PD parameter.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>the extraction is incomplete or inconsistent.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted.</td></tr><tr><td><span class="pk-badge pk-badge--green">▶ simulatable</span></td><td>the paper's popPK model runs per phenotype in the browser (Simulation tab); its PGx Modelica model is under Models.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">model only</span></td><td>a PGx Modelica model exists but has no in-browser simulator.</td></tr></tbody></table></details>

<details class="legend">
<summary>What the PGx columns mean</summary>
<table><thead><tr><th>column</th><th>what it holds</th></tr></thead><tbody><tr><td><code>gene</code></td><td>the gene whose variants the record is about. One record per gene, so a paper reporting several genes appears on several rows.</td></tr><tr><td><code>affects</code></td><td>the PK or PD parameter the genotype SHIFTS, as an ontology Q-code plus its name — Q22 = clearance, Q27 = CL/F (apparent clearance), Q32 = Cmax, Q88 = AUC, Q40 = Fab, Q321 = EC50, Q322 = IC50, Q305 = kfm. The record's per-phenotype theta is a multiplier ON that parameter: a poor-metaboliser theta shifts this value, it does not supply one. Two values are NOT parameters — Q100 (NIL) is an association or risk finding with no parameter target, and `safety` is an adverse-reaction risk such as an HLA allele. A PA… id instead of a Q-code marks a record derived from a ClinPGx/PharmGKB guideline lookup rather than read out of the paper.</td></tr><tr><td><code>mechanism</code></td><td>how the gene acts: metabolism, transport, target, formation, safety_allele, or unknown.</td></tr><tr><td><code>detail</code></td><td>the paper stem, linking to the full record page.</td></tr><tr><th colspan="2" style="text-align:left;padding-top:10px">placeholders</th></tr><tr><td><code>not captured</code></td><td>the field is absent from the KB artifact — nothing was recorded. This is NOT the same as zero or empty: the value is unknown, not measured to be nothing.</td></tr><tr><td><code>—</code></td><td>deliberately not shown: the column does not apply to this row.</td></tr><tr><td><code>not verified</code></td><td>the record is not in an accepted state (see the badge and the note above the table); the numbers are shown as extracted, not endorsed.</td></tr></tbody></table>
</details>

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=quinapril) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | small intestine | `SLC15A1` substrate | DrugBank actor |
| distribution | blood | `ALB` binder | DrugBank actor |
| metabolism | liver | `CES1` formation/substrate | DrugBank actor |
| excretion | kidney | `SLC15A2` substrate, `SLC22A8` substrate | DrugBank actor |

<sub>Actors without a tissue in the table: ACE (inhibitor), ACE (target).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 51 matched, 48 returned
- **screened:** 8  ·  **relevant:** 1
- **records:** 0  ·  extracted 0  ·  needs_review 0  ·  rejected 0  ·  stale 0
- **scholar-agent fallback query used:** True

## Full text wanted

_4 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Chu_2007.pdf` | Chu XY et al., Transport of the dipeptidyl peptidase-4…, The Journal of pharmacology… (2007) | pd | 4 | [10.1124/jpet.106.116517](https://doi.org/10.1124/jpet.106.116517) | [17314201](https://www.ncbi.nlm.nih.gov/pubmed/17314201) | metadata signals extractable PD data (IC50) |
| `Lin_1999.pdf` | Lin CJ et al., Competitive inhibition of glycylsarcosi…, Pharmaceutical research (1999) | pd | 4 | [10.1023/a:1018847818766](https://doi.org/10.1023/a:1018847818766) | [10350000](https://www.ncbi.nlm.nih.gov/pubmed/10350000) | metadata signals extractable PD data (IC50) |
| `Müns_1993.pdf` | Müns G et al., Regulation of angiotensin I-converting…, Journal of cellular biochem… (1993) | pd | 4 | [10.1002/jcb.240530413](https://doi.org/10.1002/jcb.240530413) | [8300752](https://www.ncbi.nlm.nih.gov/pubmed/8300752) | metadata signals extractable PD data (IC50) |
| `Reid_1991.pdf` | Reid JL et al., The contribution of ambulatory blood pr…, Journal of hypertension. Su… (1991) | pd | 4 | not captured | [1795202](https://www.ncbi.nlm.nih.gov/pubmed/1795202) | metadata signals extractable PD data (concentration-effect) |

<sub>queue written 2026-09-30T23:42:57.281471+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Afonso_2013 | irrelevant | 2 | 0 | This is a pharmacodynamic (ACE inhibition) study in horses; no PK disposition parameters (CL, V, ka, half-life) for quinapril are reported, only PD metrics like Imax and AUC of inhibition. |
| popPK | Becker_2021 | irrelevant | 0 | 0 | A case report/review on ACE inhibitor angioedema with no PK parameters or numeric disposition values for quinapril. |
| PD | Becker_2021 | not_relevant | 1 | 0 | Case report with only qualitative discussion of ACE-inhibitor PD; no numeric PD parameters or concentration/dose-effect data. |
| popPK | Begg_1989 | irrelevant | 3 | 0 | A narrative review/discussion of ACE inhibitor PK in renal impairment with no numeric quinapril parameter values present. |
| PD | Begg_1989 | not_relevant | 2 | 0 | Narrative review of ACE inhibitor PK/PD in renal impairment; only qualitative statements about prolonged ACE inhibition, no numeric PD parameters or effect-concentration data. |
| popPK | Begg_1990 | relevant | 7 | 3 | PK study of quinapril/quinaprilat in renal impairment, but the evidence gives only summary statements (clearance–CLCr relationships, half-life trends) without actual numeric parameter values, which are not provided. |
| popPK | Breslin_1996 | relevant | 6 | 3 | PK study of quinapril/quinaprilat in humans, but evidence gives only summary values (bioavailability ~50%, AUC comparisons) without CL/V/t½ or model parameters, which may be in figures/tables not provided. |
| popPK | Cabré_2026 | irrelevant | 0 | 0 | Narrative review of cardiovascular pharmacotherapy with no quinapril PK parameters or numeric values. |
| PD | Cabré_2026 | not_relevant | 1 | 0 | Narrative review of cardiovascular pharmacotherapy with no quinapril-specific PD or exposure-response data or numeric parameters. |
| popPK | Canter_1994 | irrelevant | 0 | 0 | This is a clinical efficacy/dose-response trial with no pharmacokinetic parameters for quinapril reported. |
| popPK | Chu_2007 | irrelevant | 0 | 0 | This is an in-vitro transporter study of sitagliptin; quinapril appears only as an OAT3 inhibitor (IC50), with no PK disposition parameters for quinapril. |
| PD | Chu_2007 | not_relevant | 0 | 0 | In vitro transporter study; quinapril appears only as an OAT3 inhibitor IC50, no in vivo PD/exposure-response relationship. |
| popPK | Elliott_1992 | relevant | 5 | 4 | Original PK study of quinapril in humans, but only a terminal half-life (26±7 h) is reported; no CL, V, or model parameters, and AUC/Cmax values are not given numerically. |
| PD | Elliott_1992 | not_relevant | 0 | 0 | not captured |
| popPK | Endlich_1995 | irrelevant | 0 | 0 | Quinapril is only used as a diagnostic ACE-inhibitor co-intervention; no PK parameters for quinapril are reported. |
| PD | Endlich_1995 | not_relevant | 1 | 1 | Quinapril is used only as a fixed-dose ACE-inhibition intervention; the concentration-response relationships (EC50, Emax) reported are for PTH/PTHRP, not for quinapril, so no quinapril exposure-response PD parameters are extractable. |
| popPK | Fernandez_1992 | irrelevant | 2 | 0 | This is a pharmacodynamic (orthostatic blood pressure) study; quinapril concentrations were sampled but no numeric PK parameters (CL, V, ka, half-life, model) appear in the evidence. |
| PD | Fernandez_1992 | not_relevant | 3 | 2 | Reports qualitative orthostatic BP/HR responses to quinapril doses with plasma concentrations sampled, but no numeric PD parameters (Emax, EC50, slope) or effect-vs-concentration relationship are stated or derivable. |
| popPK | Fernández-Llaneza_2025 | irrelevant | 0 | 0 | This is a drug-safety/AKI knowledge-integration study; quinapril is merely listed among nephrotoxicity-potential drugs, with no PK parameters reported. |
| PD | Fernández-Llaneza_2025 | not_relevant | 0 | 0 | This is a knowledge-aggregation/safety-signal study on drug-induced AKI (RORs, ADE frequencies); no quinapril concentration-effect or dose-response PD data or parameters are reported. |
| popPK | Fiscon_2021 | irrelevant | 0 | 0 | This is a network-based drug repurposing study for COVID-19 with no pharmacokinetic parameters for quinapril (quinapril is not even mentioned). |
| PD | Fiscon_2021 | not_relevant | 0 | 0 | Network-based computational drug repurposing study; no quinapril exposure-, dose-, or concentration-effect data or PD parameters are reported. |
| popPK | Frank_1990 | irrelevant | 2 | 0 | This is a clinical overview of efficacy/safety with no quantitative PK parameters for quinapril reported. |
| PD | Frank_1990 | not_relevant | 1 | 0 | Narrative review summarizing trial counts and safety; no numeric PD or dose-response parameters reported. |
| popPK | Frohlich_1990 | irrelevant | 0 | 0 | Pharmacodynamic study of ACE inhibitors in rats with no pharmacokinetic parameters or numeric disposition values for quinapril. |
| PD | Frohlich_1990 | not_relevant | 2 | 0 | Qualitative comparison of ACE inhibitor effects on cardiovascular mass/function in rats; no concentration- or dose-response data or numeric PD parameters reported. |
| popPK | Frohlich_1991 | irrelevant | 0 | 0 | Pharmacodynamic/hemodynamic study in rats with no PK parameters or numeric disposition values for quinapril. |
| PD | Frohlich_1991 | not_relevant | 2 | 1 | Animal dose-comparison study of ACE inhibitors reporting qualitative hemodynamic/structural effects with no concentration-effect data or numeric PD parameters. |
| popPK | González-Correa_2025 | irrelevant | 0 | 0 | The study concerns hydrochlorothiazide and a probiotic in rats; quinapril is not the subject drug and no PK parameters appear. |
| PD | González-Correa_2025 | not_relevant | 2 | 0 | Animal study of probiotic potentiation of HCTZ antihypertensive effects; no concentration-effect or dose-response PD parameters (Emax, EC50, slope) reported or derivable. |
| PGx | Hallberg_2017 | not_relevant | 2 | 3 | The paper reports genetic associations with ACE inhibitor-induced cough (an adverse event), not with any pharmacokinetic or pharmacodynamic parameter of quinapril. |
| popPK | Ikemura_2019 | irrelevant | 0 | 0 | In-vitro CYP2J2 inhibition study; quinapril is only one of many tested inhibitors (IC50/Ki for enzyme inhibition), with no PK disposition parameters. |
| PD | Ikemura_2019 | not_relevant | 1 | 2 | In vitro recombinant CYP2J2 enzyme inhibition study (IC50/Ki for quinapril), not an in vivo exposure-response or dose-effect PD relationship. |
| popPK | Jallapally_2015 | irrelevant | 0 | 0 | This is a medicinal chemistry/ACE inhibition potency study; quinapril is only a comparator and no PK parameters are reported. |
| PD | Jallapally_2015 | not_relevant | 2 | 2 | In vitro ACE IC50 values for novel peptidomimetics (quinapril only as comparator), not an in-vivo exposure- or dose-response PD relationship for quinapril. |
| popPK | Johnston_1989 | irrelevant | 1 | 0 | This is an in vitro/ex vivo tissue ACE inhibition study with no PK disposition parameters (CL, V, ka, etc.) or numeric PK values for quinapril. |
| PD | Johnston_1989 | not_relevant | 3 | 1 | Qualitative review of tissue ACE inhibition with rank-order potency and dose-dependent inhibition described, but no numeric PD parameters (Emax, EC50, curves) extractable. |
| popPK | Keuneke_1990 | irrelevant | 1 | 0 | This is a narrative review of tissue RAS effects with no quinapril PK parameters; no numeric values present. |
| PD | Keuneke_1990 | not_relevant | 1 | 0 | Narrative review of tissue RAS mechanisms; no numeric PD or dose/concentration-effect parameters for quinapril are reported or derivable. |
| popPK | Kieback_2009 | irrelevant | 3 | 1 | This is a narrative review of quinaprilat (the active metabolite) with no original quantitative PK parameters (CL, V, ka) reported in the evidence. |
| PD | Kieback_2009 | not_relevant | 2 | 1 | A narrative review summarizing quinaprilat PK/PD qualitatively; no numeric PD parameters (Emax, EC50, effect curves) are reported or derivable from the abstract. |
| popPK | Kim_2000 | irrelevant | 1 | 0 | Quinapril is used only as a co-administered ACE inhibitor in a bradykinin pharmacodynamic study; no PK parameters for quinapril are reported. |
| popPK | Kim_2022 | irrelevant | 0 | 0 | This is a zebrafish neuroprotection screening study with no quinapril PK parameters reported. |
| PD | Kim_2022 | not_relevant | 0 | 0 | This is an in vivo zebrafish screening study for neuroprotective compounds; quinapril is not mentioned and no drug exposure-response or concentration-effect PD relationship with numeric parameters is reported. |
| popPK | Kimura_1998 | irrelevant | 0 | 0 | This is a vascular pharmacodynamics study of adrenoceptor sensitivity with no PK parameters (CL, V, ka, half-life, or PK model) for quinapril reported. |
| popPK | Lee_2026 | irrelevant | 0 | 0 | This is a survey study of natural health product-drug interactions in New Zealand with no pharmacokinetic parameters for quinapril or any drug. |
| PD | Lee_2026 | not_relevant | 0 | 0 | Survey/coding feasibility study of NHP use; no quinapril concentration- or dose-effect data or PD parameters. |
| popPK | Lin_1999 | irrelevant | 1 | 1 | In-vitro transporter inhibition study; quinapril is only a test inhibitor, no PK disposition parameters reported. |
| PD | Lin_1999 | not_relevant | 3 | 4 | In vitro transporter inhibition IC50/Ki values for quinapril/quinaprilat are reported, but this is a biochemical BBMV uptake study, not an in vivo exposure- or dose-response PD relationship for the drug. |
| popPK | Maeso_1999 | irrelevant | 0 | 0 | This is a vascular pharmacology study using quinapril as a treatment, with no PK parameters reported. |
| PD | Maeso_1999 | not_relevant | 2 | 1 | Preclinical rat study with fixed-dose quinapril; dose-response curves are for acetylcholine in isolated vessels, not a quinapril exposure/dose-effect relationship with extractable PD parameters. |
| popPK | Müns_1993 | irrelevant | 0 | 0 | In-vitro enzyme inhibition study; quinapril is only an ACE inhibitor with an IC50, no PK disposition parameters. |
| popPK | Oosterga_2000 | irrelevant | 0 | 0 | This is a vascular pharmacodynamics study of ACE inhibition with no PK parameters (CL, V, ka, half-life, or PK model) for quinapril reported. |
| popPK | Padoin_1998 | irrelevant | 2 | 1 | Quinapril is only the interacting co-administered drug; all quantitative PK parameters (CL, ka, AUC) reported are for cephalexin, not quinapril. |
| PD | Padoin_1998 | not_relevant | 0 | 0 | This is a purely pharmacokinetic interaction study (quinapril effects on cephalexin PK parameters); no pharmacodynamic or exposure-response relationship is modeled or reported. |
| popPK | Plosker_1994 | irrelevant | 2 | 1 | This is a narrative review of pharmacology/efficacy with only a half-life mentioned and no quantitative PK parameters (CL, V, ka) or model values reported. |
| PD | Plosker_1994 | not_relevant | 1 | 0 | Narrative review with only qualitative dose-range statements (10–40 mg/day efficacy) and no concentration-effect data or numeric PD parameters. |
| popPK | Qi_2001 | irrelevant | 0 | 0 | This is a mechanistic cardiac physiology study using quinapril as a therapy, with no pharmacokinetic parameters reported. |
| PD | Qi_2001 | not_relevant | 2 | 1 | Animal in-vitro ET-1 dose-response study with qualitative quinapril effects; no quinapril exposure-response relationship or numeric PD parameters (Emax, EC50, etc.) reported or derivable. |
| popPK | Reid_1991 | irrelevant | 1 | 0 | This is a review/abstract on ambulatory blood pressure monitoring; no PK parameters or numeric values for quinapril are reported. |
| PD | Reid_1991 | not_relevant | 2 | 0 | Abstract/review-style mention of using ABPM to assess quinapril dose and concentration-effect relationships, with no numeric PD parameters or effect-vs-concentration data reported. |
| popPK | Schaison_1996 | irrelevant | 1 | 0 | This is a pharmacodynamic dose-response study of ACE inhibition in rats with no PK parameters (CL, V, ka, half-life, or PK model) reported for quinapril. |
| popPK | Somogyi-Végh_2019 | irrelevant | 0 | 0 | This is a drug-drug interaction prevalence study with no pharmacokinetic parameters for quinapril; quinapril is not even mentioned. |
| PD | Somogyi-Végh_2019 | not_relevant | 0 | 0 | This is a drug-utilization/DDI prevalence study with no concentration-effect, dose-response, or PK/PD analysis for quinapril; no PD parameters are reported or derivable. |
| popPK | Song_2002 | irrelevant | 2 | 0 | This is a review of other ACE inhibitors; quinapril is only mentioned as an established comparator with no quantitative PK parameters reported. |
| PD | Song_2002 | not_relevant | 2 | 1 | This is a narrative review; quinapril is only mentioned qualitatively (flat dose-response class statement, mortality overview) with no numeric PD parameters or effect-vs-concentration data extractable. |
| popPK | Tarkiainen_2015 | relevant | 6 | 2 | Quinapril is a subject drug in a PK study, but the evidence contains no numeric PK parameter values for quinapril (likely in tables/figures not provided). |
| PD | Tarkiainen_2015 | not_relevant | 0 | 0 | This is a genotype-stratified pharmacokinetic study (CES1 c.428G&gt;A effect on quinapril/enalapril disposition) with no pharmacodynamic endpoint, concentration-effect, or dose-response data reported. |
| PD | Wolter_1993 | not_relevant | 3 | 2 | Small-n PK/PD study showing ACE activity suppression and MAP/Ang II changes after 2.5 mg quinapril, but only qualitative concentration-effect description; no numeric PD parameters (Emax, EC50, slope) or effect-vs-concentration curve are reported or derivable. |
| popPK | Wright_2025 | irrelevant | 0 | 0 | This is a population-PK study of colchicine, not quinapril; quinapril is not the subject drug and no quinapril parameters appear. |
| PD | Wright_2025 | not_relevant | 0 | 0 | This is a population PK model for colchicine (not quinapril) with only a nominal concentration range used as a safety/efficacy proxy; no drug-effect vs exposure relationship or PD parameters are modeled or derivable. |
| popPK | Yilmaz_2026 | irrelevant | 0 | 0 | Clinical vascular-function trial with no PK parameters or numeric disposition values for quinapril. |
| popPK | Yuan_2009 | relevant | 4 | 3 | Quinapril/quinaprilat is the subject drug with some PK values (AUC change, urinary excretion change, Km), but no CL/V/compartment parameters and no full PK model values are provided. |
| PD | Yuan_2009 | not_relevant | 2 | 1 | The paper reports a transporter-mediated DDI (Km/IC50 values) and qualitative synergistic blood pressure reduction, but no concentration-effect or dose-response PD relationship for quinapril with extractable PD parameters. |
| popPK | Zhao_2025 | irrelevant | 0 | 0 | This is a metabolomics drug-screening library paper; quinapril is only mentioned as an example of spectral analog matching, with no PK parameters reported. |
| PD | Zhao_2025 | not_relevant | 0 | 0 | Metabolomics-based drug exposure detection resource; no quinapril concentration-effect or dose-response PD analysis or parameters. |

---
<sub>Generated by `docs.py` (scholarv2)</sub>
